Inject at least 2 inches away from the navel
Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents (Toxicology and Applied Pharmacology)
B12 and nausea reduction Nausea is the most common side effect of GLP-1 and GLP-1/GIP receptor agonists
This neurotropic combination (Thiamine B1 + Pyridoxine B6 + Cyanocobalamin B12) is used for: peripheral neuropathy (diabetic/alcoholic), nerve compression syndromes, vitamin deficiency states, and chronic pain management
While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions
It has a genuine FDA-approval history rather than being a novel "research chemical," but no FDA-approved finished product remains on the market, so it is supplied only through compounding pharmacies and prescribed off-label in adults for growth-hormone-axis support, general wellness, or anti-aging purposes rather than its original pediatric indication
